CIK 0001601830 · Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464099738
- Phone
- (385) 269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-19 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +40,000 | 953,839 | ||
| 2025-12-19 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −40,000 | $4.50 | $180K | 913,839 |
| 2025-12-19 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −40,000 | 4,723,334 | ||
| 2025-12-15 | Taylor Ben R Chief Financial Officer | Shares withheld for taxes | −7,057 | $4.33 | $31K | 782,933 |
| 2025-12-04 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +60,000 | 973,839 | ||
| 2025-12-04 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −40,000 | $4.63 | $185K | 933,839 |
| 2025-12-04 | Gibson Christopher Chief Executive Officer | Gift 10b5-1 | −20,000 | 913,839 | ||
| 2025-12-04 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −60,000 | 4,763,334 | ||
| 2025-12-02 | Borgeson Blake Director | Sale 10b5-1 | −220,000 | $4.37 | $961K | 6,869,863 |
| 2025-11-25 | Taylor Ben R Chief Financial Officer | Shares withheld for taxes | −2,271 | $4.03 | $9K | 789,990 |
| 2025-11-19 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +40,000 | 953,839 | ||
| 2025-11-19 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −40,000 | $4.16 | $166K | 913,839 |
| 2025-11-19 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −40,000 | 4,823,334 | ||
| 2025-11-17 | Khan Najat Chief R&D Commercial Officer | Shares withheld for taxes | −17,584 | $4.14 | $73K | 735,538 |
| 2025-11-17 | Gibson Christopher Chief Executive Officer | Shares withheld for taxes 10b5-1 | −40,390 | $4.14 | $167K | 913,839 |
| 2025-11-17 | Taylor Ben R Chief Financial Officer | Shares withheld for taxes | −11,908 | $4.14 | $49K | 792,261 |
| 2025-11-05 | Khan Najat Chief R&D Commercial Officer | Grant or award | +84,925 | 753,122 | ||
| 2025-11-05 | Khan Najat Chief R&D Commercial Officer | Grant or award · Stock Option (Right to Buy) | +169,851 | 169,851 | ||
| 2025-11-04 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +60,000 | 1,014,229 | ||
| 2025-11-04 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −40,000 | $5.21 | $208K | 974,229 |
Page 6 of 9 · 179 trades